Novel first-dose adverse drug reactions during a phase I trial of olipudase alfa (recombinant human acid sphingomyelinase) in adults with Niemann-Pick disease type B (acid sphingomyelinase deficiency)

Margaret M. McGovern, Melissa P. Wasserstein, Brian Kirmse, W. Lane Duvall, Thomas Schiano, Beth L. Thurberg, Susan Richards, Gerald F. Cox

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose:Enzyme replacement therapy with olipudase alfa (recombinant human acid sphingomyelinase) is being developed for Niemann-Pick disease type B (NPD B).Methods:A single-center, open-label, nonrandomized, single-ascending-dose trial evaluated the safety of intravenous olipudase alfa (0.03-1.0 mg/kg) in 11 adults with NPD B. Patients were monitored in the hospital for 72 h after infusion and had follow-up visits on days 14 and 28.Results:Plasma ceramide, a product of sphingomyelin catabolism by olipudase alfa, showed dose-dependent elevations by 6 h postdose, or postinfusion. No serious adverse drug reactions (ADRs) occurred during the study. Acute phase reaction-type ADRs, as evidenced by elevated inflammatory biomarkers (high-sensitivity C-reactive protein, interleukin-8, and calcitonin) and constitutional symptoms (fever, pain, nausea, and/or vomiting) emerged 12-24 h following doses ≥0.3 mg/kg olipudase alfa. Three patients experienced hyperbilirubinemia. The study was terminated after a patient dosed at 1 mg/kg exhibited severe hyperbilirubinemia; he was subsequently diagnosed with Gilbert syndrome.Conclusion:The maximum tolerated dose of olipudase alfa in adults with NPD B was 0.6 mg/kg. First-dose ADRs were likely induced by elevated concentrations of ceramide (or its downstream derivatives) generated by the catabolism of accumulated sphingomyelin. Within-patient dose escalation to slowly catabolize sphingomyelin stores may be a strategy to mitigate first-dose ADRs in patients with NPD B.

Original languageEnglish (US)
Pages (from-to)34-40
Number of pages7
JournalGenetics in Medicine
Volume18
Issue number1
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Type B Niemann-Pick Disease
Type A Niemann-Pick Disease
Sphingomyelin Phosphodiesterase
Drug-Related Side Effects and Adverse Reactions
Sphingomyelins
Acids
Hyperbilirubinemia
Ceramides
Gilbert Disease
Enzyme Replacement Therapy
Acute-Phase Reaction
Maximum Tolerated Dose
Calcitonin
Interleukin-8
C-Reactive Protein
Nausea
Vomiting
Fever
Biomarkers
olipudase alfa

Keywords

  • acute phase reaction
  • ceramide
  • hyperbilirubinemia
  • Niemann-Pick disease type B
  • recombinant human acid sphingomyelinase

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Novel first-dose adverse drug reactions during a phase I trial of olipudase alfa (recombinant human acid sphingomyelinase) in adults with Niemann-Pick disease type B (acid sphingomyelinase deficiency). / McGovern, Margaret M.; Wasserstein, Melissa P.; Kirmse, Brian; Duvall, W. Lane; Schiano, Thomas; Thurberg, Beth L.; Richards, Susan; Cox, Gerald F.

In: Genetics in Medicine, Vol. 18, No. 1, 01.01.2016, p. 34-40.

Research output: Contribution to journalArticle

McGovern, Margaret M. ; Wasserstein, Melissa P. ; Kirmse, Brian ; Duvall, W. Lane ; Schiano, Thomas ; Thurberg, Beth L. ; Richards, Susan ; Cox, Gerald F. / Novel first-dose adverse drug reactions during a phase I trial of olipudase alfa (recombinant human acid sphingomyelinase) in adults with Niemann-Pick disease type B (acid sphingomyelinase deficiency). In: Genetics in Medicine. 2016 ; Vol. 18, No. 1. pp. 34-40.
@article{919d7a154d93408081b38950a484576c,
title = "Novel first-dose adverse drug reactions during a phase I trial of olipudase alfa (recombinant human acid sphingomyelinase) in adults with Niemann-Pick disease type B (acid sphingomyelinase deficiency)",
abstract = "Purpose:Enzyme replacement therapy with olipudase alfa (recombinant human acid sphingomyelinase) is being developed for Niemann-Pick disease type B (NPD B).Methods:A single-center, open-label, nonrandomized, single-ascending-dose trial evaluated the safety of intravenous olipudase alfa (0.03-1.0 mg/kg) in 11 adults with NPD B. Patients were monitored in the hospital for 72 h after infusion and had follow-up visits on days 14 and 28.Results:Plasma ceramide, a product of sphingomyelin catabolism by olipudase alfa, showed dose-dependent elevations by 6 h postdose, or postinfusion. No serious adverse drug reactions (ADRs) occurred during the study. Acute phase reaction-type ADRs, as evidenced by elevated inflammatory biomarkers (high-sensitivity C-reactive protein, interleukin-8, and calcitonin) and constitutional symptoms (fever, pain, nausea, and/or vomiting) emerged 12-24 h following doses ≥0.3 mg/kg olipudase alfa. Three patients experienced hyperbilirubinemia. The study was terminated after a patient dosed at 1 mg/kg exhibited severe hyperbilirubinemia; he was subsequently diagnosed with Gilbert syndrome.Conclusion:The maximum tolerated dose of olipudase alfa in adults with NPD B was 0.6 mg/kg. First-dose ADRs were likely induced by elevated concentrations of ceramide (or its downstream derivatives) generated by the catabolism of accumulated sphingomyelin. Within-patient dose escalation to slowly catabolize sphingomyelin stores may be a strategy to mitigate first-dose ADRs in patients with NPD B.",
keywords = "acute phase reaction, ceramide, hyperbilirubinemia, Niemann-Pick disease type B, recombinant human acid sphingomyelinase",
author = "McGovern, {Margaret M.} and Wasserstein, {Melissa P.} and Brian Kirmse and Duvall, {W. Lane} and Thomas Schiano and Thurberg, {Beth L.} and Susan Richards and Cox, {Gerald F.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1038/gim.2015.24",
language = "English (US)",
volume = "18",
pages = "34--40",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Novel first-dose adverse drug reactions during a phase I trial of olipudase alfa (recombinant human acid sphingomyelinase) in adults with Niemann-Pick disease type B (acid sphingomyelinase deficiency)

AU - McGovern, Margaret M.

AU - Wasserstein, Melissa P.

AU - Kirmse, Brian

AU - Duvall, W. Lane

AU - Schiano, Thomas

AU - Thurberg, Beth L.

AU - Richards, Susan

AU - Cox, Gerald F.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Purpose:Enzyme replacement therapy with olipudase alfa (recombinant human acid sphingomyelinase) is being developed for Niemann-Pick disease type B (NPD B).Methods:A single-center, open-label, nonrandomized, single-ascending-dose trial evaluated the safety of intravenous olipudase alfa (0.03-1.0 mg/kg) in 11 adults with NPD B. Patients were monitored in the hospital for 72 h after infusion and had follow-up visits on days 14 and 28.Results:Plasma ceramide, a product of sphingomyelin catabolism by olipudase alfa, showed dose-dependent elevations by 6 h postdose, or postinfusion. No serious adverse drug reactions (ADRs) occurred during the study. Acute phase reaction-type ADRs, as evidenced by elevated inflammatory biomarkers (high-sensitivity C-reactive protein, interleukin-8, and calcitonin) and constitutional symptoms (fever, pain, nausea, and/or vomiting) emerged 12-24 h following doses ≥0.3 mg/kg olipudase alfa. Three patients experienced hyperbilirubinemia. The study was terminated after a patient dosed at 1 mg/kg exhibited severe hyperbilirubinemia; he was subsequently diagnosed with Gilbert syndrome.Conclusion:The maximum tolerated dose of olipudase alfa in adults with NPD B was 0.6 mg/kg. First-dose ADRs were likely induced by elevated concentrations of ceramide (or its downstream derivatives) generated by the catabolism of accumulated sphingomyelin. Within-patient dose escalation to slowly catabolize sphingomyelin stores may be a strategy to mitigate first-dose ADRs in patients with NPD B.

AB - Purpose:Enzyme replacement therapy with olipudase alfa (recombinant human acid sphingomyelinase) is being developed for Niemann-Pick disease type B (NPD B).Methods:A single-center, open-label, nonrandomized, single-ascending-dose trial evaluated the safety of intravenous olipudase alfa (0.03-1.0 mg/kg) in 11 adults with NPD B. Patients were monitored in the hospital for 72 h after infusion and had follow-up visits on days 14 and 28.Results:Plasma ceramide, a product of sphingomyelin catabolism by olipudase alfa, showed dose-dependent elevations by 6 h postdose, or postinfusion. No serious adverse drug reactions (ADRs) occurred during the study. Acute phase reaction-type ADRs, as evidenced by elevated inflammatory biomarkers (high-sensitivity C-reactive protein, interleukin-8, and calcitonin) and constitutional symptoms (fever, pain, nausea, and/or vomiting) emerged 12-24 h following doses ≥0.3 mg/kg olipudase alfa. Three patients experienced hyperbilirubinemia. The study was terminated after a patient dosed at 1 mg/kg exhibited severe hyperbilirubinemia; he was subsequently diagnosed with Gilbert syndrome.Conclusion:The maximum tolerated dose of olipudase alfa in adults with NPD B was 0.6 mg/kg. First-dose ADRs were likely induced by elevated concentrations of ceramide (or its downstream derivatives) generated by the catabolism of accumulated sphingomyelin. Within-patient dose escalation to slowly catabolize sphingomyelin stores may be a strategy to mitigate first-dose ADRs in patients with NPD B.

KW - acute phase reaction

KW - ceramide

KW - hyperbilirubinemia

KW - Niemann-Pick disease type B

KW - recombinant human acid sphingomyelinase

UR - http://www.scopus.com/inward/record.url?scp=84954341716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954341716&partnerID=8YFLogxK

U2 - 10.1038/gim.2015.24

DO - 10.1038/gim.2015.24

M3 - Article

VL - 18

SP - 34

EP - 40

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 1

ER -